A team committed to the development of a therapeutic portfolio in hearing loss

WHO ARE WE ?

Sensorion is a pioneering clinical-stage biotech company, dedicated to the development of innovative therapies to restore, treat and prevent within the field of hearing loss

Géraldine Honnet, M.D.

Chief Medical Officer

20 years in clinical development and gene therapy
Formerly Director of Development, Genethon and Medical Director, Parexel International
Previously Senior Clinical Manager, Transgene

Nawal Ouzren

CEO and Director

15 years in pharmaceutical operations and strategic management
Formerly VP and Head, Hemophilia Franchise, Baxalta (within Shire)
Formerly Group Vice President, Rare Genetic Diseases, Shire

David Lawrence

Advisor to the CEO

30 years’ experience of leadership roles in life sciences
Previously Chief Financial Officer of Valneva
Formerly co-founder and Board member of Synpromics Ltd.

Stéphanie Filipe

Head of the Project Management Office

15 years in therapeutic products development in Biotechs from bench to beside including gene and cell therapies
Formerly R&D Director at OTR3, Program Leader at Cellectis
Ph.D., Cellular Biology & Biochemistry

Laurent Désiré

Head of Preclinical Development

Over 15 years in pharmaceutical R&D and clinical development, especially in gene therapy and neuroscience
Formerly Head of Cellular and Molecular Biology unit at YposKesi, and R&D Executive Director at Diaxonhit and ExonHit
Ph.D., Biology of Aging

Judith Laredo

Clinical Research Director

20 years in clinical research monitoring
Formerly Alliance Manager Oncology and Head of Translational Research, Servier
Ph.D., Pharmacology and Toxicology

Christine Le Bec

Head of CMC Gene Therapy

25 years in production process development for gene therapy
Formerly Head of CMC analytical department, Genethon
Ph.D., Biochemistry and Analytical Chemistry

Valérie Salentey

Director of Regulatory Affairs & Quality Assurance

Over 15 years in Regulatory Affairs and Quality Assurance in Biologics and advanced therapies
Formerly headed Regulatory Affairs at Cytheris, Généthon, PPD, Neovacs
Doctor of Pharmacy (PharmD)

Rachel Cooper

Head of Audiology

Over 23 years in the hearing health industry
Formerly Global Professional Marketing Manager at Cochlear Ltd.
Doctor of Audiology (AuD), Cochlear Implant Specialty Certification (CISC), Pediatric Audiology Specialty Certification (PASC), Executive MBA

Khalil Barrage

Interim Chairman of the Board

Director, Representative of Invus
15 years of experience in portfolio management at The Olayan Group in New York
Managing Director for the Invus Group in New York and Board member of Protagenic and Celtaxsys

Nawal Ouzren

CEO and Director

15 years in pharmaceutical operations and strategic management
Formerly VP and Head, Hemophilia Franchise, Baxalta (within Shire)
Formerly Group Vice President, Rare Genetic Diseases, Shire

Julien Miara

Director, Representative of Invus

10 years of experience in investment, covering biotechnology among other sectors
Director at Invus

Cédric Moreau

Director representing Sofinnova Partners

18 years of experience in investment banking and in life sciences
Partner in the Crossover investment team at Sofinnova Partners

Natalie Berner

Director representing Redmile Group

Managing Director specializing in therapeutic products at Redmile
Former Research Associate at New York University School of Medicine
Bachelor’s degree in Community Health from Brown University and Certificate in Premedical Sciences from Columbia University
Member of two other boards: Redx Pharma and BioInvent

Eric de la Fortelle

Independent Director

10 years of experience as scientific researcher in biotechnology, CEO and member of several Boards
Venture Partner at Seventure Partners

John Furey

Independent Director

20 years of experience as CEO and Chief Operating Officer in pharmaceutical societies
CEO of Imvax
Non Executive Director at Adaptimmune

Aniz Girach

Independent Director

M.D., over 22 years’ experience in the pharma industry
CMO at ProQR Therapeutics
Member of three Scientific Advisory Boards

Florian Reinaud

Board Observer Redmile Group

Special Advisor Europe for Redmile Group
20 years experience in Healthcare Innovation and Capital Investment
Former emergency physician in the UK’s National Health Service
MD., awarded with Distinction from Imperial College London and holds a BA(hons) in Physiology from the University of Oxford
Board Member of Sensome

Pr Christine Petit

Chair of the Scientific Advisory Board

Chair of Genetics and Cellular Physiology, Professor at College de France and at Institut Pasteur (Paris)
Head of the Laboratory of Genetics and Physiology of Hearing at Institut Pasteur
Managing Director of the French Hearing Institute
Member of the French and American Sciences Academies and the American Medical Academy

Pr Alain Fischer

Professor at College de France
Former director and founding member of the Institute for Genetic Diseases (Imagine)
Former director of the pediatric immuno-hematology department at Necker Hospital

Dr Robert Dow

More than 37 years of experience in the pharmaceutical and biotech industry
Former Chief Medical Officer at PPD Inc.
Substantial experience across therapeutic areas from pre-clinical to Phase 3 development

Pr Paul Avan

Physicist and Medical Doctor in Biophysics
Head of the Center for Research and Innovation in Human Audiology at Hearing Institute (Paris)
Designed original objective methods of exploration of the cochlea and auditory pathways

Dr. Diane Lazard

ENT Surgeon and former Head of Clinic at AP-HP
Principal Associate Investigator at the Hearing Institute (Paris)
Currently pursuing research on deciphering language processing variability in deafness

Dr. Hernán López-Schier

Senior Group Leader and Research Unit Director at the Helmholtz Center in Munich
Currently pursuing research on fundamental sensory biology and sensory dysfunction
His group was the first to visualize the regeneration of mechanosensory hair cells in their natural context